EBV-Associated Tumors: Pathogenetic Insights for Improved Disease Monitoring and Treatment

被引:10
作者
Dolcetti, Riccardo [1 ]
Guidoboni, Massimo [1 ]
Gloghini, Annunziata [2 ]
Carbone, Antonino [2 ]
机构
[1] Natl Canc Inst, IRCCS, CRO, Immunovirol & Biotherapy Unit,Dept Preclin & Epid, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy
[2] Natl Canc Inst, IRCCS, CRO, Dept Pathol, Aviano, PN, Italy
关键词
Epstein-Barr virus; lymphoma; histogenesis; DNA load; immune suppression; AIDS;
D O I
10.2174/1573394052952528
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epstein-Barr virus (EBV) is a ubiquitous gamma-herpes virus that is a well-established risk factor for Hodgkin's lymphoma, Burkitt's lymphoma, a subset of T cell lymphomas and various tumors of epithelial cell origin with nasopharyngeal carcinoma as the most representative. Furthermore, EBV-associated lymphoproliferative disorders are a well recognized major complication of immune suppression. EBV generally establishes a life-long asymptomatic infection in memory B lymphocytes, by mimicking cellular signaling pathways that regulate antigen-dependent B cell differentiation. In the long-lived memory B lymphocyte pool, the virus is almost completely silent or expresses a very restricted set of latent proteins, evading thus the immune control by EBV-specific effectors. EBV-associated lymphoid and epithelial malignancies are characterized by a peculiar geographic distribution and distinctive epidemiologic and histopathologic and histogenetic features. Moreover, new histogenetic and molecular features have contributed to the recognition and the diagnosis of specific disease categories. The ability of the virus to establish life-long persistent infections in humans and to contribute to cell transformation is related to the biologic properties of a set of EBV-encoded proteins, differently expressed in both normal and transformed cells. In the last decade, our understanding of the latency programs activated by EBV in cellular backgrounds and the function of EBV-encoded proteins has considerably improved. The emerging picture indicates that EBV proteins are able to hijack critical cellular pathways to promote the proliferation and survival of infected cells, while impairing anti-viral immune responses. The recent advances in the elucidation of the mechanisms underlying EBV-induced cell transformation and immune evasion help to design novel treatment approaches for EBV-related malignancies. Moreover, it has been clearly shown that the quantification of circulating EBV DNA is a valuable tool in the diagnosis, clinical monitoring and prognosis of some EBV-associated tumors.
引用
收藏
页码:27 / 44
页数:18
相关论文
共 212 条
[11]   Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma:: comparison with Hodgkin's disease [J].
Beck, A ;
Päzolt, D ;
Grabenbauer, GG ;
Nicholls, JM ;
Herbst, H ;
Young, LS ;
Niedobitek, G .
JOURNAL OF PATHOLOGY, 2001, 194 (02) :145-151
[12]   Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity [J].
Bollard, CM ;
Rössig, C ;
Calonge, MJ ;
Huls, MH ;
Wagner, HJ ;
Massague, J ;
Brenner, MK ;
Heslop, HE ;
Rooney, CM .
BLOOD, 2002, 99 (09) :3179-3187
[13]  
Boshoff C, 1999, CANCER SURV, V33, P157
[14]   Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma [J].
Bräuninger, A ;
Hansmann, ML ;
Strickler, JG ;
Dummer, R ;
Burg, G ;
Rajewsky, K ;
Küppers, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (16) :1239-1247
[15]   siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells [J].
Butz, K ;
Ristriani, T ;
Hengstermann, A ;
Denk, C ;
Scheffner, M ;
Hoppe-Seyler, F .
ONCOGENE, 2003, 22 (38) :5938-5945
[16]   Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EμLMP2A transgenic mice [J].
Caldwell, RG ;
Brown, RG ;
Longnecker, R .
JOURNAL OF VIROLOGY, 2000, 74 (03) :1101-1113
[17]   Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo [J].
Callan, MFC ;
Tan, L ;
Annels, N ;
Ogg, GS ;
Wilson, JDK ;
O'Callaghan, CA ;
Steven, N ;
McMichael, AJ ;
Rickinson, AB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (09) :1395-1402
[18]   AIDS-related primary brain lymphomas: Histopathologic and immunohistochemical study of 51 cases [J].
CamilleriBroet, S ;
Davi, F ;
Feuillard, J ;
Seilhean, D ;
Michiels, JF ;
Brousset, P ;
Epardeau, B ;
Navratil, E ;
Mokhtari, K ;
Bourgeois, C ;
Marelle, L ;
Raphael, M ;
Hauw, JJ .
HUMAN PATHOLOGY, 1997, 28 (03) :367-374
[19]  
Capello D, 2000, BLOOD, V95, P651
[20]   Molecular histogenesis of posttransplantation lymphoproliferative disorders [J].
Capello, D ;
Cerri, M ;
Muti, G ;
Berra, E ;
Oreste, P ;
Deambrogi, C ;
Rossi, D ;
Dotti, G ;
Conconi, A ;
Viganò, M ;
Magrini, U ;
Ippoliti, G ;
Morra, E ;
Gloghini, A ;
Rambaldi, A ;
Paulli, M ;
Carbone, A ;
Gaidano, G .
BLOOD, 2003, 102 (10) :3775-3785